Switching to Bictegravir, Emtricitabine, and Tenofovir Alafenamide in Virologically Suppressed Adults With Human Immunodeficiency Virus

Paul E Sax, Jürgen K Rockstroh, Anne F Luetkemeyer, Yazdan Yazdanpanah, Douglas Ward, Benoit Trottier, Armin Rieger, Hui Liu, Rima Acosta, Sean E Collins, Diana M Brainard, Hal Martin, GS-US-380–4030 Investigators, Paul E Sax, Jürgen K Rockstroh, Anne F Luetkemeyer, Yazdan Yazdanpanah, Douglas Ward, Benoit Trottier, Armin Rieger, Hui Liu, Rima Acosta, Sean E Collins, Diana M Brainard, Hal Martin, GS-US-380–4030 Investigators

Abstract

Background: Bictegravir (B)/emtricitabine (F)/tenofovir alafenamide (TAF) is guideline-recommended treatment for human immunodeficiency virus type 1 (HIV-1). We evaluated whether people receiving dolutegravir (DTG) plus F/TAF or F/TDF (tenofovir disoproxil fumarate) with viral suppression can switch to B/F/TAF without compromising safety or efficacy, regardless of preexisting nucleoside reverse transcriptase inhibitor (NRTI) resistance.

Methods: In this multicenter, randomized, double-blinded, active-controlled, noninferiority trial, we enrolled adults who were virologically suppressed for ≥6 months before screening (with documented/suspected NRTI resistance) or ≥3 months before screening (with no documented/suspected NRTI resistance) on DTG plus either F/TDF or F/TAF. We randomly assigned (1:1) participants to switch to B/F/TAF or DTG + F/TAF once daily for 48 weeks, each with matching placebo. The primary endpoint was proportion of participants with plasma HIV-1 RNA ≥50 copies/mL at week 48 (snapshot algorithm); the prespecified noninferiority margin was 4%.

Results: Five hundred sixty-seven adults were randomized; 565 were treated (284 B/F/TAF, 281 DTG + F/TAF). At week 48, B/F/TAF was noninferior to DTG + F/TAF, as 0.4% (1/284) vs 1.1% (3/281) had HIV-1 RNA ≥50 copies/mL (difference, -0.7% [95.001% confidence interval {CI}, -2.8% to 1.0%]). There were no significant differences in efficacy among participants with suspected or confirmed prior NRTI resistance (n = 138). No participant had treatment-emergent drug resistance. Median weight change from baseline at week 48 was +1.3 kg (B/F/TAF) vs +1.1 kg (DTG + F/TAF) (P = .46). Weight change differed by baseline NRTIs (+2.2 kg [F/TDF] and +0.6 kg [F/TAF], P < .001), with no differences between B/F/TAF and DTG + F/TAF.

Conclusions: The single-tablet regimen B/F/TAF is a safe, effective option for people virologically suppressed on DTG plus either F/TDF or F/TAF, including in individuals with preexisting resistance to NRTIs.

Clinical trials registration: NCT03110380.

Keywords: HIV; INSTI; bictegravir; dolutegravir; tenofovir alafenamide.

© The Author(s) 2020. Published by Oxford University Press for the Infectious Diseases Society of America.

Figures

Figure 1.
Figure 1.
Study profile through week 48. Abbreviations: B/F/TAF, bictegravir/emtricitabine/tenofovir alafenamide; DTG + F/TAF, dolutegravir plus emtricitabine/tenofovir alafenamide.
Figure 2.
Figure 2.
Virologic outcome at week 48. Abbreviations: B/F/TAF, bictegravir/emtricitabine/tenofovir alafenamide; c/mL, copies per milliliter; CI, confidence interval; DTG + F/TAF, dolutegravir plus emtricitabine/tenofovir alafenamide; HIV-1 human immunodeficiency virus type 1.

References

    1. European AIDS Clinical Society. Guidelines, version 9.1, October 2018. Available at: . Accessed 21 March 2020.
    1. Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in adults and adolescents living with HIV.2019. Available at: . Accessed 21 March 2020.
    1. Saag MS, Benson CA, Gandhi RT, et al. . Antiretroviral drugs for treatment and prevention of HIV infection in adults: 2018 recommendations of the International Antiviral Society–USA panel. JAMA 2018; 320:379–96.
    1. Walmsley SL, Antela A, Clumeck N, et al. . SINGLE Investigators . Dolutegravir plus abacavir-lamivudine for the treatment of HIV-1 infection. N Engl J Med 2013; 369:1807–18.
    1. Raffi F, Jaeger H, Quiros-Roldan E, et al. . extended SPRING-2 Study Group . Once-daily dolutegravir versus twice-daily raltegravir in antiretroviral-naive adults with HIV-1 infection (SPRING-2 study): 96 week results from a randomised, double-blind, non-inferiority trial. Lancet Infect Dis 2013; 13:927–35.
    1. Gallant J, Lazzarin A, Mills A, et al. . Bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir, abacavir, and lamivudine for initial treatment of HIV-1 infection (GS-US-380-1489): a double-blind, multicentre, phase 3, randomised controlled non-inferiority trial. Lancet 2017; 390:2063–72.
    1. Sax PE, Pozniak A, Montes ML, et al. . Coformulated bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir with emtricitabine and tenofovir alafenamide, for initial treatment of HIV-1 infection (GS-US-380-1490): a randomised, double-blind, multicentre, phase 3, non-inferiority trial. Lancet 2017; 390:2073–82.
    1. Aboud M, Kaplan R, Lombaard J, et al. . Dolutegravir versus ritonavir-boosted lopinavir both with dual nucleoside reverse transcriptase inhibitor therapy in adults with HIV-1 infection in whom first-line therapy has failed (DAWNING): an open-label, non-inferiority, phase 3b trial. Lancet Infect Dis 2019; 19:253–64.
    1. Cahn P, Pozniak AL, Mingrone H, et al. . Extended SAILING Study Team . Dolutegravir versus raltegravir in antiretroviral-experienced, integrase-inhibitor-naive adults with HIV: week 48 results from the randomised, double-blind, non-inferiority SAILING study. Lancet 2013; 382:700–8.
    1. Demarest J, Underwood M, St Clair M, Dorey D, Brown D, Zolopa A. Short communication: dolutegravir-based regimens are active in integrase strand transfer inhibitor-naive patients with nucleoside reverse transcriptase inhibitor resistance. AIDS Res Hum Retroviruses 2018; 34:343–6.
    1. Daar ES, DeJesus E, Ruane P, et al. . Efficacy and safety of switching to fixed-dose bictegravir, emtricitabine, and tenofovir alafenamide from boosted protease inhibitor-based regimens in virologically suppressed adults with HIV-1: 48 week results of a randomised, open-label, multicentre, phase 3, non-inferiority trial. Lancet HIV 2018; 5:e347–56.
    1. Molina JM, Ward D, Brar I, et al. . Switching to fixed-dose bictegravir, emtricitabine, and tenofovir alafenamide from dolutegravir plus abacavir and lamivudine in virologically suppressed adults with HIV-1: 48 week results of a randomised, double-blind, multicentre, active-controlled, phase 3, non-inferiority trial. Lancet HIV 2018; 5:e357–65.
    1. Clinical Trial Facilitation Group (CTFG). Recommendations related to contraception and pregnancy testing in clinical trials. 2014. Available at: . Accessed 21 March 2020.
    1. World Health Organization. Potential safety issue affecting women living with HIV using dolutegravir at the time of conception. Geneva, Switzerland.2018. Available at: . Accessed 21 March 2020.
    1. Panel on Treatment of Pregnant Women with HIV Infection and Prevention of Perinatal Transmission. Recommendations for use of antiretroviral drugs in transmission in the United States. Available at: . Accessed 21 March 2020.
    1. US Food and Drug Administration. FDA drug safety communication: FDA to evaluate potential risk of neural tube birth defects with HIV medicine dolutegravir (Juluca, Tivicay, Triumeq). Available at: . Accessed 21 March 2020.
    1. Wensing AM, Calvez V, Günthard HF, et al. . 2017 Update of the drug resistance mutations in HIV-1. Top Antivir Med 2016; 24:132–3.
    1. Smith F, Hammerstorm T, Soon G, et al. . A meta-analysis to assess the FDA DAVP’s TLOVR algorithm in HIV submissions. Drug Inf J 2011; 45:291–300.
    1. Tsiang M, Jones GS, Goldsmith J, et al. . Antiviral activity of bictegravir (GS-9883), a novel potent HIV-1 integrase strand transfer inhibitor with an improved resistance profile. Antimicrob Agents Chemother 2016; 60:7086–97.
    1. Oliveira M, Ibanescu RI, Anstett K, et al. . Montreal Primary HIV (PHI) Cohort Study Group . Selective resistance profiles emerging in patient-derived clinical isolates with cabotegravir, bictegravir, dolutegravir, and elvitegravir. Retrovirology 2018; 15:56.
    1. Porter DP, Toma J, Tan Y, et al. . Clinical outcomes of virologically-suppressed patients with pre-existing HIV-1 drug resistance mutations switching to rilpivirine/emtricitabine/tenofovir disoproxil fumarate in the SPIRIT study. HIV Clin Trials 2016; 17:29–37.
    1. Trottier B, Lake JE, Logue K, et al. . Dolutegravir/abacavir/lamivudine versus current ART in virally suppressed patients (STRIIVING): a 48-week, randomized, non-inferiority, open-label, phase IIIb study. Antivir Ther 2017; 22:295–305.
    1. Elion RA, Althoff KN, Zhang J, et al. . North American AIDS Cohort Collaboration on Research and Design of IeDEA . Recent abacavir use increases risk of type 1 and type 2 myocardial infarctions among adults with HIV. J Acquir Immune Defic Syndr 2018; 78:62–72.
    1. Sabin CA, Worm SW, Weber R, et al. . D:A:D Study Group . Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients enrolled in the D:A:D study: a multi-cohort collaboration. Lancet 2008; 371:1417–26.
    1. Friis-Møller N, Reiss P, Sabin CA, et al. . DAD Study Group . Class of antiretroviral drugs and the risk of myocardial infarction. N Engl J Med 2007; 356:1723–35.
    1. Holmberg SD, Moorman AC, Williamson JM, et al. . HIV Outpatient Study (HOPS) Investigators . Protease inhibitors and cardiovascular outcomes in patients with HIV-1. Lancet 2002; 360:1747–8.
    1. Sax PE, Erlandson KM, Lake JE, et al. . Weight gain following initiation of antiretroviral therapy: risk factors in randomized comparative clinical trials. Clin Infect Dis 2020; 71:1379–89.
    1. Gatell JM, Assoumou L, Moyle G, et al. . NEAT022 Study Group . Switching from a ritonavir-boosted protease inhibitor to a dolutegravir-based regimen for maintenance of HIV viral suppression in patients with high cardiovascular risk. AIDS 2017; 31:2503–14.
    1. Cahn P, Madero JS, Arribas JR, et al. . GEMINI Study Team . Dolutegravir plus lamivudine versus dolutegravir plus tenofovir disoproxil fumarate and emtricitabine in antiretroviral-naive adults with HIV-1 infection (GEMINI-1 and GEMINI-2): week 48 results from two multicentre, double-blind, randomised, non-inferiority, phase 3 trials. Lancet 2019; 393:143–55.
    1. Glidden DV, Mulligan K, McMahan V, et al. . Metabolic effects of preexposure prophylaxis with coformulated tenofovir disoproxil fumarate and emtricitabine. Clin Infect Dis 2018; 67:411–9.
    1. Grant RM, Lama JR, Anderson PL, et al. . iPrEx Study Team . Preexposure chemoprophylaxis for HIV prevention in men who have sex with men. N Engl J Med 2010; 363:2587–99.
    1. Hare CB, Coll J, Ruane P, et al. . The phase 3 DISCOVER study: daily F/TAF or F/TDF for HIV preexposure prophylaxis [abstract 104LB]. In: Conference of Retroviruses and Opportunistic Infections, Seattle, WA, March 4–7, 2019. Available at: . Accessed 21 March 2020.

Source: PubMed

Sponsor e collaboratori

Condizioni mediche

Interventi farmacologici

3
Sottoscrivi